Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative

Purpose: To broaden access to and implementation of precision medicine in the care of patients with pancreatic cancer, the Know Your Tumor (KYT) program was initiated using a turn-key precision medicine system. Patients undergo commercially available multiomic profiling to determine molecularly rationalized clinical trials and off-label therapies. Experimental Design: Tumor samples were obtained…

Read the full article here

Source: Clinical Cancer Research

Categories: Hem/Oncs

Tags: PancreaticCancer

Tweets with this article

Anirban Maitra

Clinical NGS paved the way for application of “real time” molecular profiling to #PancreaticCancer patients, as demonstrated here: https://t.co/xEZRTjwWSi & here: https://t.co/lPgEh9vIx5 In 2019, @NCCN updated its guidelines to recommend universal germline testing for all pts. https://t.co/7E6jjMWcLa

A neoantigen vaccine generates antitumour immunity in renal cell carcinoma

Nature – A phase I trial of a neoantigen-targeting personalized cancer vaccine led to durable and polyfunctional T cell responses and antitumour recognition, and was…

Anirban Maitra February 11, 2025

Pfizer | Knock Out

Pfizer is fighting for 8 cancer breakthroughs by 2030.

Anirban Maitra February 10, 2025

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

PURPOSESWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly…

Anirban Maitra February 8, 2025

LINE-1 ORF1p Mimics Viral Innate Immune Evasion Mechanisms in Pancreatic Ductal Adenocarcinoma

Abstract. Repeat element viral mimicry is a common feature in pancreatic ductal adenocarcinoma (PDAC) that require mechanisms to manage this repeat “viral” load and attenuate…

Anirban Maitra February 7, 2025

Stromal KITL/SCF maintains pancreas tissue homeostasis and restrains tumor progression

Abstract. Components of normal tissue architecture serve as barriers to tumor progression. Inflammatory and wound-healing programs are requisite features of solid tumorigenesis, wherein alterations to…

Anirban Maitra February 7, 2025

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

PURPOSESWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly…

Anirban Maitra February 7, 2025

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

PURPOSESWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly…

Anirban Maitra February 7, 2025

Related Articles